DAA (direct acting antiviral) – new hepatitis C drugs that work directly against the hepatitis C virus (HCV).
Since 2014, the following DAAs have been approved – and more are in development:
sofosbuvir, ledipasvir, simeprevir, daclatasvir, ombitasvir, paritaprevir/r, dasabuvir, elbasvir, grazoprevir and velapatasvir.
Previously, HCV was treated with pegylated interferon (PEG-IFN) plus ribavirin (RBV).
Even though HCV guidelines now only recommend DAA treatment, the high price of DAAs means that in many countries these medicines are only available to people who have advanced liver damage.
Note: this page is only to enable an error with an earlier published hyperlink (to dda instead of daa)